Coating bacteria for anti-tumor therapy

Wang, Jiahui; Guo, Ning; Hou, Weiliang; Qin, Huanlong

doi:10.3389/fbioe.2022.1020020

Cited by 5 publications

(4 citation statements)

References 135 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, its clinical translation is greatly limited due to its worries of biosafety and high clearance rate in vivo. Biomimetic cell-surface coating may be a successful method to improve biocompatibility and reduce the elimination of living bacteria by macrophages [32,38,115]. A novel approach was introduced to enhance antitumor targeting by employing a red blood cell membrane-coated "invisibility cloak" for the probiotic E. coli Nissle 1917 (EcN) [116].…”

Section: Biomimetic Cell-surface Coatingmentioning

confidence: 99%

Bacteria and Bacterial Components as Natural Bio-Nanocarriers for Drug and Gene Delivery Systems in Cancer Therapy

Zong,

Ruan,

Liu

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Bacteria and bacterial components possess multifunctional properties, making them attractive natural bio-nanocarriers for cancer diagnosis and targeted treatment. The inherent tropic and motile nature of bacteria allows them to grow and colonize in hypoxic tumor microenvironments more readily than conventional therapeutic agents and other nanomedicines. However, concerns over biosafety, limited antitumor efficiency, and unclear tumor-targeting mechanisms have restricted the clinical translation and application of natural bio-nanocarriers based on bacteria and bacterial components. Fortunately, bacterial therapies combined with engineering strategies and nanotechnology may be able to reverse a number of challenges for bacterial/bacterial component-based cancer biotherapies. Meanwhile, the combined strategies tend to enhance the versatility of bionanoplasmic nanoplatforms to improve biosafety and inhibit tumorigenesis and metastasis. This review summarizes the advantages and challenges of bacteria and bacterial components in cancer therapy, outlines combinatorial strategies for nanocarriers and bacterial/bacterial components, and discusses their clinical applications.

show abstract

Section: Biomimetic Cell-surface Coatingmentioning

confidence: 99%

Bacteria and Bacterial Components as Natural Bio-Nanocarriers for Drug and Gene Delivery Systems in Cancer Therapy

Zong,

Ruan,

Liu

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…As targeted carriers, nanomaterials surface‐modified with different molecules like chemotherapeutic drugs and genes present an ideal solution for minimizing damage to normal cells and mitigating undesired toxicity 22,23 . They can not only improve bacterial adhesion and colonization at tumor sites but also provide precise control over drug solubility, stability, and release in the intracellular and extracellular environment 24–26 . As therapeutic agents, multifunctional nanomaterials bestow oncolytic bacteria with characteristics that surpass their inherent capabilities.…”

Section: Introductionmentioning

confidence: 99%

“… 22 , 23 They can not only improve bacterial adhesion and colonization at tumor sites but also provide precise control over drug solubility, stability, and release in the intracellular and extracellular environment. 24 , 25 , 26 As therapeutic agents, multifunctional nanomaterials bestow oncolytic bacteria with characteristics that surpass their inherent capabilities. The physicochemical properties of nanomaterials allow oncolytic bacterial therapy to synergize therapeutic effects with photothermal therapy (PTT), photodynamic therapy (PDT), chemotherapy, radiotherapy, immunotherapy, and other modalities.…”

Section: Introductionmentioning

confidence: 99%

Nanomaterial‐assisted oncolytic bacteria in solid tumor diagnosis and therapeutics

Zeng,

Chen,

Chen

2024

Bioengineering & Transla Med

View full text Add to dashboard Cite

Cancer presents a formidable challenge in modern medicine due to the intratumoral heterogeneity and the dynamic microenvironmental niche. Natural or genetically engineered oncolytic bacteria have always been hailed by scientists for their intrinsic tumor‐targeting and oncolytic capacities. However, the immunogenicity and low toxicity inevitably constrain their application in clinical practice. When nanomaterials, characterized by distinctive physicochemical properties, are integrated with oncolytic bacteria, they achieve mutually complementary advantages and construct efficient and safe nanobiohybrids. In this review, we initially analyze the merits and drawbacks of conventional tumor therapeutic approaches, followed by a detailed examination of the precise oncolysis mechanisms employed by oncolytic bacteria. Subsequently, we focus on harnessing nanomaterial‐assisted oncolytic bacteria (NAOB) to augment the effectiveness of tumor therapy and utilizing them as nanotheranostic agents for imaging‐guided tumor treatment. Finally, by summarizing and analyzing the current deficiencies of NAOB, this review provides some innovative directions for developing nanobiohybrids, intending to infuse novel research concepts into the realm of solid tumor therapy.

show abstract

“…These advancements include the development of bacterial membrane-encapsulated nano-drug delivery systems and bacterial-nanoparticle hybridization systems. These innovations not only promote the application of bacteria but also offer new opportunities for optimizing protocols in tumor treatment ( Cacicedo et al, 2018 ; Hou et al, 2021 ; Li et al, 2022 ; Wang et al, 2022 ; Xie et al, 2022 ). This article aimed to summarize the genetic editing or engineering techniques used in several facultative anaerobes and other bacteria for antitumor therapy and to discuss the potential future directions in drug delivery vehicles.…”

Section: Introductionmentioning

confidence: 99%

Advances in anti-tumor based on various anaerobic bacteria and their derivatives as drug vehicles

Song,

Yang,

Chen

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Cancer therapies, such as chemotherapy and radiotherapy, are often unsatisfactory due to several limitations, including drug resistance, inability to cross biological barriers, and toxic side effects on the body. These drawbacks underscore the need for alternative treatments that can overcome these challenges and provide more effective and safer options for cancer patients. In recent years, the use of live bacteria, engineered bacteria, or bacterial derivatives to deliver antitumor drugs to specific tumor sites for controlled release has emerged as a promising therapeutic tool. This approach offers several advantages over traditional cancer therapies, including targeted drug delivery and reduced toxicity to healthy tissues. Ongoing research in this field holds great potential for further developing more efficient and personalized cancer therapies, such as E. coli, Salmonella, Listeria, and bacterial derivatives like outer membrane vesicles (OMVs), which can serve as vehicles for drugs, therapeutic proteins, or antigens. In this review, we describe the advances, challenges, and future directions of research on using live bacteria or OMVs as carriers or components derived from bacteria of delivery systems for cancer therapy.

show abstract

Coating bacteria for anti-tumor therapy

Cited by 5 publications

References 135 publications

Bacteria and Bacterial Components as Natural Bio-Nanocarriers for Drug and Gene Delivery Systems in Cancer Therapy

Bacteria and Bacterial Components as Natural Bio-Nanocarriers for Drug and Gene Delivery Systems in Cancer Therapy

Nanomaterial‐assisted oncolytic bacteria in solid tumor diagnosis and therapeutics

Advances in anti-tumor based on various anaerobic bacteria and their derivatives as drug vehicles

Contact Info

Product

Resources

About